Opthea Limited, an Australian clinical-stage biopharmaceutical company specializing in treatments for retinal diseases, has recently faced significant challenges. The company's flagship clinical trial for its wet age-related macular degeneration (wet AMD) treatment, sozinibercept (OPT-302), failed to meet its primary endpoints. This outcome has raised concerns about Opthea's solvency, as it may trigger repayment obligations exceeding $1 billion to its funders.
The trial's failure has also impacted major investors. For instance, Regal Funds, which had a position valued at approximately $214 million in Opthea, saw the value of its investment plummet, resulting in a loss exceeding $100 million.
TYR Price at posting:
76.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)